Grants to Oncoheroes Sample Clauses

Grants to Oncoheroes. At Oncoheroes’ request and sole cost and expense, Notable shall assign (or cause to be assigned) to Oncoheroes or its designee (or to the extent not so assignable, Notable shall take all reasonable actions requested by Oncoheroes to make available to Oncoheroes or its designee the benefits of) all Clinical Data, Regulatory Filings, and Regulatory Approvals for the Licensed Product in the Licensed Field, made or owned by Notable and its Affiliates and/or sublicensees. Subject to the royalty obligations set forth in this Section 13.6.4(a), Notable shall further grant to Oncoheroes with effect from the effective date of termination an exclusive license, with the right to grant sublicenses (through multiple tiers of sublicensees), under the Notable Inventions (but not any Notable Background Technology) solely to Exploit the Licensed Product in the Territory. In each case, unless otherwise required by any Applicable Law or regulation or requested by Oncoheroes, the foregoing assignment and license shall be made within sixty (60) calendar days after the effective date of any termination of this Agreement. Upon termination of this Agreement by Notable pursuant to Section 13.4.2, in exchange for the foregoing license, Oncoheroes shall pay royalties to Notable for Exploiting the Licensed Product as follows: (a) royalty-free if termination occurs prior to initiation of a Clinical Study by Notable on the Licensed Product in the Licensed Field; (b) a royalty percentage of [****] percent ([****]%) if such termination occurs on or after initiation of the first Clinical Study by Notable for a Licensed Product but prior to the first Regulatory Approval in the Territory; and (c) a royalty percentage of [****] percent ([****]%) if such termination occurs on or after the first Regulatory Approval in the Licensed Field. To the extent any assignment of Clinical Data, Regulatory Filings, and Regulatory Approvals hereunder is not legally permissible or does not relate solely to the Licensed Product, Notable shall, subject to the foregoing royalties, grant Oncoheroes the exclusive license and right (with the right to Sublicense) to access, use, and cross-reference such Clinical Data, Regulatory Filings and Regulatory Approvals solely to Develop, Manufacture and Commercialize the Licensed Products in the Territory.
Sample 1
AutoNDA by SimpleDocs

Related to Grants to Oncoheroes

  • RIGHTS TO NAME If the Adviser ceases to act as investment adviser to the Trust or any Fund whose name includes the term "Golden" (the "Xxxx") or if the Adviser requests in writing, the Trust shall take prompt action to change the name of the Trust or any such Fund to a name that does not include the Xxxx. The Adviser may from time to time make available without charge to the Trust for the Trust's use any marks or symbols owned by the Adviser, including marks or symbols containing the Xxxx or any variation thereof, as the Adviser deems appropriate. Upon the Adviser's request in writing, the Trust shall cease to use any such xxxx or symbol at any time. The Trust acknowledges that any rights in or to the Xxxx and any such marks or symbols which may exist on the date of this Agreement or arise hereafter are, and under any and all circumstances shall continue to be, the sole property of the Adviser. The Adviser may permit other parties, including other investment companies, to use the Xxxx in their names without the consent of the Trust. The Trust shall not use the Xxxx in conducting any business other than that of an investment company registered under the 1940 Act without the permission of the Adviser.

  • PAYMENTS TO PURCHASER 52 ARTICLE VI....................................................................54

  • Statements to Purchaser Not later than the tenth calendar day of the month, the Company shall furnish in an agreed upon electronic format to the Purchaser or its designee, a monthly, loan level, scheduled remittance advice, trial balance report and payment and payoff activity detail, as to the preceding remittance and the period ending on the last day of the preceding month.

  • Reports to Administrator Each Series shall furnish or otherwise make available to the Administrator such copies of that Series's Prospectus, SAI, financial statements, proxy statements, reports, and other information relating to its business and affairs as the Administrator may, at any time or from time to time, reasonably require in order to discharge its obligations under this Agreement.

  • Reports to Adviser The Trust shall furnish or otherwise make available to the Adviser such copies of each Fund 's Prospectus, Statement of Additional Information, financial statements, proxy statements, reports and other information relating to its business and affairs as the Adviser may, at any time or from time to time, reasonably require in order to discharge its obligations under this Agreement.

  • Conditions to Purchases No Purchase Commitment or Purchase shall be entered into unless each of the following conditions is satisfied (or waived as provided below) as of the date (such Portfolio Investment’s “Trade Date”) on which such Purchase Commitment is entered into (and such Portfolio Investment shall not be Purchased, and the related Financing shall not be required to be made available to the Company by the applicable Financing Providers, unless each of the following conditions is satisfied or waived as of such Trade Date):

  • Rights to Purchase There are no outstanding agreements, options, rights of first refusal, conditional sales agreements or other agreements or arrangements, whether oral or written, regarding the purchase and sale of the Property, or which otherwise affect any portion of or all the Property. The representation contained in this Section 5.21 shall be true at and as of Closing.

  • No Rights to Service Nothing contained in this Agreement shall be construed as giving Participant any right to be retained, in any position, as an employee, consultant or director of the Company or its Affiliates or shall interfere with or restrict in any way the right of the Company or its Affiliates, which is hereby expressly reserved, to remove, terminate or discharge Participant at any time for any reason whatsoever.

  • Reports to Board Custodian shall provide written reports notifying the Board of the placement of Assets with a particular Foreign Custodian and of any material change in a Series’ foreign custody arrangements. Such reports shall be provided to the Board quarterly, except as otherwise agreed by the Custodian and the Fund.

  • Amendments to Purchase Agreement 11. The parties agree that the Purchase Agreement shall be amended, solely with respect to the Mortgage Loans, as follows:

Time is Money Join Law Insider Premium to draft better contracts faster.